Literature DB >> 3002439

Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei.

Y Pommier, R E Schwartz, L A Zwelling, K W Kohn.   

Abstract

Intercalator-induced DNA double-strand breaks (DSB) presumably represent topoisomerase II DNA cleavage sites in mammalian cells. Isolated L1210 cell nuclei were used to determine the saturability of this reaction at high drug concentrations. 4'-(9-Acridinylamino)methanesulfon-m-anisidide (m-AMSA) and 5-iminodaunorubicin (5-ID) both produced DSB in a concentration-dependent manner, and the production of these breaks leveled off above 10 microM. Addition of m-AMSA to 5-ID-treated nuclei did not raise the plateau level. Thus, both drugs seemed to interact similarly on identical targets. The ellipticine derivative 2-methyl-9-hydroxyellipticinium (2-Me-9-OH-E+) had two effects on the production of DSB. Below 10 microM, 2-Me-9-OH-E+ produced DSB as did ellipticine, m-AMSA, or 5-ID. Above 10 microM, 2-Me-9-OH-E+ did not induce DSB and inhibited the DSB induced by m-AMSA, 5-ID, or ellipticine. 2-Me-9-OH-E+ and m-AMSA competed with each other to produce either double-strand break formation (m-AMSA-induced reaction) or double-strand break inhibition (2-Me-9-OH-E+-induced reaction at concentrations greater than 10 microM). Because these results were reproduced in experiments using DNA topoisomerase II isolated from L1210 nuclei, it is likely that the intercalator-induced protein-associated DNA breaks detected by alkaline elution in nuclei represent DNA topoisomerase II-DNA complexes.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3002439     DOI: 10.1021/bi00344a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Anthracycline antibiotic arugomycin binds in both grooves of the DNA helix simultaneously: an NMR and molecular modelling study.

Authors:  M S Searle; W Bicknell; L P Wakelin; W A Denny
Journal:  Nucleic Acids Res       Date:  1991-06-11       Impact factor: 16.971

Review 2.  Targeting DNA topoisomerase II in cancer chemotherapy.

Authors:  John L Nitiss
Journal:  Nat Rev Cancer       Date:  2009-04-20       Impact factor: 60.716

3.  Development of a novel assay for human tyrosyl DNA phosphodiesterase 2.

Authors:  Sanjay Adhikari; Soumendra K Karmahapatra; Hadi Elias; Priyanka Dhopeshwarkar; R Scott Williams; Stephen Byers; Aykut Uren; Rabindra Roy
Journal:  Anal Biochem       Date:  2011-05-12       Impact factor: 3.365

4.  Mechanisms of small molecule-DNA interactions probed by single-molecule force spectroscopy.

Authors:  Ali A Almaqwashi; Thayaparan Paramanathan; Ioulia Rouzina; Mark C Williams
Journal:  Nucleic Acids Res       Date:  2016-04-16       Impact factor: 16.971

Review 5.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.

Authors:  M L Wong; M T Hsu
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

7.  Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II.

Authors:  M Tarr; P D van Helden
Journal:  Mol Cell Biochem       Date:  1990-03-27       Impact factor: 3.396

8.  Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes.

Authors:  Sonya C Tang; Theresa A Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2009-12-14       Impact factor: 5.191

9.  Anthracycline-based combined chemotherapy in the mouse model.

Authors:  M Popovic; J Kolarovic; M Mikov; S Trivic; B Kaurinovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Apr-Jun       Impact factor: 2.441

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.